Amity University Madhya Pradesh hosted its Convocation Ceremony for its class of 2024 in a grand and dignified atmosphere, on ...

Since the start of this week\u0026#39;s trading, the EUR/USD pair has been attempting to rebound upwards, with gains reaching ...

The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the ...

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

Bernstein analyst Florent Cespedes maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK620.00.

The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

The FDA today declared the national deficit of GLP-1 diet drugs at an end. Well, at least for Novo Nordisk's Ozempic and Wegovy. Novo Nordisk sales should be going up, and Hims & Hers Health's ...

Novo Nordisk A/S's recent 44% decline combined with impressive Q4 2024 and fiscal 2024 results with strong sales and profit growth raise the question if the company is a “Buy” again.

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...